Prostate Cancer News and Research

Latest Prostate Cancer News and Research

AVIS donates health research project focuses on cancer biomarkers

The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.

24 Jun 2010

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

The Cancer Prevention and Research Institute of Texas has granted $3.7 million to Rice University researchers to fund an innovative cancer diagnostics program.

24 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Monitoring can be the best treatment for men with prostate cancer of the low-risk type, according to a study now being published in the Journal of the National Cancer Institute. The lead author is Pär Stattin, a urologist at Umeå University.

23 Jun 2010

Recent study shows drinking coffee protects against head and neck cancer

Data on the effects of coffee on cancer risk have been mixed. However, results of a recent study add to the brewing evidence that drinking coffee protects against cancer, this time against head and neck cancer.

23 Jun 2010

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospital Centre) in Pointe - Pitre (urology department, University of the French West Indies and Guiana) and from the Center for Analytical Research and Technology (University of Li-ge, Belgique), show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer.

23 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

EIN News expands health news-monitoring coverage

With impending lawsuits from states, an uprising from the Tea Party sect and an outpouring of rhetoric from both major parties, the healthcare debate is far from over.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

AVIS donates health research project focuses on cancer biomarkers

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

UK cancer survival rates increase at 3% each year

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Recent study shows drinking coffee protects against head and neck cancer

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

Ostarine increases muscle mass and strength in postmenopausal women: Study

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

EIN News expands health news-monitoring coverage

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Active surveillance sufficient for patients with low-risk prostate cancer

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

AdnaGen signs option agreement to license specific antibodies to KellBenx

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

CINJ researchers combine series of vaccination injections to treat prostate cancer

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in